Novo Nordisk fights to keep Medicaid paying for weight-loss drugs
By Dan Levine and Chad Terhune (Reuters) -Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as some U.S. states struggle with the treatment’s costs, according to state documents, company emails and interviews with lawmakers and advocates. Novo’s lobbying efforts helped to convince 14 U.S. …
Novo Nordisk fights to keep Medicaid paying for weight-loss drugs Read More »









